Tyrosine kinase inhibitors (TKIs) are used to treat a variety of cancer types. The current diagnostic tools lack the predictive power to match the right patient with the right TKI. KinaSense is developing technologies that can be used to predict whether a given patient will benefit from a specific TKI.